共 50 条
- [1] Ledipasvir Plus Sofosbuvir for 12 Weeks in Patients With Hepatitis C Genotype 4 Infection[J]. HEPATOLOGY, 2016, 64 (04) : 1049 - 1056Abergel, ArmandMetivier, SophieSamuel, DidierJiang, DeyuanKersey, KathrynPang, Phillip S.Svarovskaia, EvgueniaKnox, Steven J.Loustaud-Ratti, VeroniqueAsselah, Tarik
- [2] No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients[J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (06) : 927 - 935Marcus, Julia L.Hurley, Leo B.Chamberland, ScottChampsi, Jamila H.Gittleman, Laura C.Korn, Daniel G.Lai, Jennifer B.Lam, Jennifer O.Pauly, Mary PatriciaQuesenberry, Charles P., Jr.Ready, JoannaSaxena, VarunSeo, Suk I.Witt, David J.Silverberg, Michael J.
- [3] Effectiveness of Ledipasvir-Sofosbuvir 12 Weeks After Hepatitis C Virus Genotype 1 Infection and the Factors Associated With Sustained Virologic Response: A Retrospective Study[J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)Alshoaibi, Ismaeel A.Al-Gamli, AbdullahAbdullah, MohammedAbdo, BasheerAlzanen, Khaled H.Alhakamy, MohammedAl-Namer, MamoonAhmed, FaisalTamesh, MuntherMahdi, WadhahAbdo, ZeyadMohammed, Marwa
- [4] Sustained virologic response rates (SVR-12) for chronic hepatitis C genotype 6 patients treated with Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir[J]. JOURNAL OF HEPATOLOGY, 2018, 68 : S284 - S285Nguyen, E.Trinh, S.Trinh, H.Nguyen, H.Nguyen, K.Levitt, B.Nguyen, M.Purohit, T.Shieh, E.Nguyen, M.
- [5] Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection[J]. GASTROENTEROLOGY, 2017, 152 (06) : 1366 - 1371Gane, Edward J.Hyland, Robert H.Yang, YinSvarovskaia, EvgueniaStamm, Luisa M.Brainard, Diana M.McHutchison, John G.Stedman, Catherine A. M.
- [6] Sofosbuvir in combination with ribavirin for 12weeks achieves 97% sustained virologic response in Japanese patients with chronic genotype 2 hepatitis C infection[J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 373 - 373Omata, MasaoNishiguchi, ShuheiUeno, YoshiyukiMochizuki, HitoshiIzumi, NamikiIkeda, FusaoToyoda, HidenoriYokosuka, OsamuNirei, KazushigeGenda, TakuyaUmemura, AkejiTakehara, TetsuoSakamoto, NaoyaNishigaki, YoichiNakane, KunioToda, NobuoIde, TatsuyaYanase, MikioHino, KeisukeBetular, JuanGao, BingIshizaki, AkinobuOmote, MasaKnox, Steven J.Symonds, William T.Mchutchison, John G.Yatsuhashi, HiroshiMizokami, Masashi
- [7] Treatment with the single-tablet regimen ledipasvir/sofosbuvir for 12weeks results in 100% sustained virologic response in Japanese patients with chronic genotype-1 hepatitis C virus infection[J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 372 - 373Mizokami, MasashiTakehara, TetsuoYokosuka, OsamuSakamoto, NaoyaKorenaga, MasaakiMochizuki, HitoshiNakane, KunioEnomoto, HirayukiYanase, MikioToyoda, HidenoriIkeda, FusaoGenda, TakuyaUmemura, TakejiYatsuhashi, HiroshiIde, TatsuyaToda, NobuoNirei, KazushigeUeno, YoshiyukiNishigaki, YoichiBetular, JuanGao, BingIshizaki, AkinobuOmote, MasaLiu, VivianPang, Phillip S.Knox, Steven J.Symonds, William T.Mchutchison, John G.Izumi, NamikiOmata, Masao
- [8] Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir plus sofosbuvir or sofosbuvir plus velpatasvir[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (01) : 99 - 106Nguyen, EmilyTrinh, SamHuy TrinhHuy NguyenKhanh NguyenDo, AivienLevitt, BrianDo, SonMy NguyenPurohit, TretaShieh, EugenieNguyen, Mindie H.
- [9] Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C[J]. OPEN FORUM INFECTIOUS DISEASES, 2014, 1 (03):O'Brien, Thomas R.Kuhs, Krystle A. LangPfeiffer, Ruth M.